Brokerage firm Jefferies Maintains its rating on ABIOMED(NASDAQ:ABMD). In a research note issued to the investors, the brokerage major Raises the price-target to $145.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Aug 9, 2016.
In a different note, On Jul 29, 2016, Jefferies said it Maintains its rating on ABIOMED. In the research note, the firm Raises the price-target to $125.00 per share. The shares have been rated ‘Buy’ by the firm.
ABIOMED (ABMD) shares turned negative on Wednesdays trading session with the shares closing down -0.7 points or -0.57% at a volume of 2,61,279. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $122.9. The peak price level was also seen at $122.9 while the days lowest was $120.49. Finally the shares closed at $121.76. The 52-week high of the shares is $124.718 while the 52-week low is $67.805. According to the latest information available, the market cap of the company is $5,240 M.
ABIOMED(ABMD) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2017 and Q1.Company reported revenue of $103.00M. Analysts had an estimated revenue of $97.23M. Earnings per share were $0.29. Analysts had estimated an EPS of $0.23.
Several Insider Transactions has been reported to the SEC. On Aug 3, 2016, Paul Thomas (director) sold 10,000 shares at $118.65 per share price.Also, On Aug 3, 2016, Henri A Termeer (director) sold 25,866 shares at $118.70 per share price.On Jul 1, 2016, Michael G Howley (VP, Global Sales & Marketing) sold 10,000 shares at $106.58 per share price, according to the Form-4 filing with the securities and exchange commission.
Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.